Istically significant period effect was found (P values i0.52). The primary statistical analysis gave an estimate of the reduction in saquinavir exposure when coadministered with rifabutin, as measured by AUC(0,8 h) and Cmax(0,8 h) of 47 (95 CI 30, 60 ) and 39 (95 CI 11, 59 ), respectively. Figure 1 illustrates the plasma concentrationtime profiles for saquinavir when administered alone (Treat
Nt populations [6,7]. Opioid treatment programs (OTPs) provide a potential framework for DAART because patients visit multiple times each week to receive opioid agonist medication. Moreover, maintenance treatment at OTPs permits prolonged DAART, which is difficult in models based on outreach workers. Based on promisingDirectly Administered Therapy for HIVFigure 1. Study screening, enrollment, and
Ine for drug testing. Plasma was stored at a central repository for resistance testing. We monitored adherence with electronic pill bottle monitors (MEMS 6 TrackCap, AARDEX Group, Ltd., Sion, Switzerland) for the first 2 months after subjects started antiretroviral therapy (ART). We selected a single medication for monitoring according to the following hierarchy: dosed most frequently, combination
Ine for drug testing. Plasma was stored at a central repository for resistance testing. We monitored adherence with electronic pill bottle monitors (MEMS 6 TrackCap, AARDEX Group, Ltd., Sion, Switzerland) for the first 2 months after subjects started antiretroviral therapy (ART). We selected a single medication for monitoring according to the following hierarchy: dosed most frequently, combination
D a randomized trial to evaluate the efficacy of DAART in OTPs.for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1.Methods Design and Follow-upWe conducted a randomized controlled trial comparing 12 months of DAART to self-administered therapy (SAT) in five Baltimore OTPs - 3 hospital associated (1 Veterans Administration) and 2
N ( ) Homeless, self-described, n ( ) Receiving public assistance or social security disability, n ( ) Employed, n ( ) CES-D short-form scorea, median (IQR) 44 (85) 8 (15) 47 (42?2) 29 (56) 20 (39) 41 (79) 8 (15) 11 (5?6) 44 (80) 11 (20) 47 (41?1) 27 (49) 12 (23) 50 (91) 8 (15) 11 (6?5) 19 (37) 17 (33) 4 (8) 7 (13) 5 (10) 27 (52) 20 (36) 18 (33) 4 (7) 7 (13) 6 (11) 24 (44)Substance abuse relatedDu
N ( ) Homeless, self-described, n ( ) Receiving public assistance or social security disability, n ( ) Employed, n ( ) CES-D short-form scorea, median (IQR) 44 (85) 8 (15) 47 (42?2) 29 (56) 20 (39) 41 (79) 8 (15) 11 (5?6) 44 (80) 11 (20) 47 (41?1) 27 (49) 12 (23) 50 (91) 8 (15) 11 (6?5) 19 (37) 17 (33) 4 (8) 7 (13) 5 (10) 27 (52) 20 (36) 18 (33) 4 (7) 7 (13) 6 (11) 24 (44)Substance abuse relatedDu
N ( ) Homeless, self-described, n ( ) Receiving public assistance or social security disability, n ( ) Employed, n ( ) CES-D short-form scorea, median (IQR) 44 (85) 8 (15) 47 (42?2) 29 (56) 20 (39) 41 (79) 8 (15) 11 (5?6) 44 (80) 11 (20) 47 (41?1) 27 (49) 12 (23) 50 (91) 8 (15) 11 (6?5) 19 (37) 17 (33) 4 (8) 7 (13) 5 (10) 27 (52) 20 (36) 18 (33) 4 (7) 7 (13) 6 (11) 24 (44)Substance abuse relatedDu